RESUMEN
The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7,548 new cervical cancer cases are diagnosed each year with 3,932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2,273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2-Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1,000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.
Asunto(s)
Infecciones por Papillomavirus , Lesiones Intraepiteliales Escamosas , Neoplasias del Cuello Uterino , Femenino , Humanos , Adulto , Persona de Mediana Edad , Anciano , Detección Precoz del Cáncer , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/epidemiología , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/epidemiología , Hospitales UniversitariosRESUMEN
INTRODUCCIÓN: La pandemia por coronavirus se diseminó mundialmente con una amplia variedad de presentaciones clínicas. Se reportó que 15% de los pacientes requirió internación en una unidad de cuidados intensivos (UCI). Estudios epidemiológicos demostraron que pacientes con ventilación mecánica invasiva (VMi) por SARS-Cov-2 presentan más riesgo de infecciones asociadas a la atención de la salud (IAAS). OBJETIVO: Describir la incidencia IAAS en adultos internados en UCI en VMi del Sanatorio Anchorena San Martín, durante la pandemia en 2020. PACIENTES Y MÉTODOS: Estudio de cohorte retrospectivo, el análisis de normalidad se efectuó mediante test Shapiro-Wilk. El análisis de regresión múltiple se realizó en forma automática, (backward selection). Para la comparación entre grupo COVID-19 y no COVID-19 se utilizó T test o Test de Wilcoxon según correspondiera; y el χ2 o el test exacto de Fisher. Todas las estimaciones de las funciones de incidencia acumuladas fueron realizadas con el paquete cmprsk. RESULTADOS: Se incluyeron 252 pacientes, 40 desarrollaron IAAS (incidencia acumulada de 15,9%), con un total de 60 eventos de IAAS. La edad (OR 0,96), cantidad de accesos venosos centrales (AVC) (OR 2,01), COVID-19 (OR 2,96) y decúbito prono (OR 2,78) se asociaron a IAAS. Desarrollar IAAS se asoció a más días de VMi y estadía en UCI. La incidencia acumulada de IAAS en pacientes NO COVID fue menor que en COVID-19. Días de VMi y mortalidad en UCI fueron mayores en pacientes con COVID. El 29,6% de los pacientes con COVID-19 desarrolló algún tipo de IAAS vs 7,1% en NO COVID. CONCLUSIÓN: Describimos la incidencia de IAAS en nuestra cohorte. La presencia de COVID-19, AVC, el decúbito prono y estadía en UCI se asociaron con mayor probabilidad de contraer una IAAS.
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread fast globally comprising a great variety of clinical presentations. It was reported that 15% of patients required admission to intensive care units (ICU). Previous epidemiological studies have reported higher risk of healthcare-associated infections (HCAI) in those patients requiring invasive mechanical ventilation (iMV) due to COVID-19. AIM: To analyze the incidence of HCAI in adults under iMV admitted to ICU of Anchorena San Martín Clinic during COVID-19 pandemic. METHODS: Retrospective cohort study, the analysis of normality was carried out using the Shapiro-Wilk test. The multiple regression analysis was performed automatically, based on backward elimination of the variables (backward selection). For the comparison between the COVID-19 and non-COVID-19 groups, the T test or Wilcoxon test was used, as appropriate; and the χ2 or Fisher's exact test. All cumulative incidence function estimates were made with the cmprsk package. RESULTS: 252 patients were included, 40 patients developed HCAI (accumulated incidence was 15.9%), counting for 60 total HCAI events. Age (OR 0.96), number of central venous access devices (CVAD) (OR 2.01), COVID-19 (OR 2.96) and prone positioning (OR 2.78) were associated with HCAI. HCAI was associated with more days of iMV and ICU stay. The accumulated incidence of HCAI in non-COVID-19 patients was lower than in COVID-19 patients. iMV days and mortality were higher in COVID-19. 29.6% of COVID-19 patients developed HCAIs vs 7.1% of non-COVID-19 ones. CONCLUSION: We describe the incidence of HCAI. Age, COVID-19, CVAD, prone positioning and ICU stay were associated with higher probability of HCAIs.